Skip to main content

Boxed Warnings:
Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurs in patients receiving Blincyto. Interrupt or discontinue Blincyto and treat with corticosteroids as recommended.
Neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS) which may be serious, life-threatening, or fatal, occurred in individuals receiving Blincyto. Interrupt or stop treatment with Blincyto injection as recommended.

Medication Guide:
Indication: Blincyto, a bispecific CD19-directed CD3 T-cell engager, is prescribed for treating both adult and pediatric patients with:
CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
Acute lymphoblastic leukemia (ALL) that has returned after treatment or does not respond to treatment and is characterized by CD19-positive B-cell precursors.

Dosage and Administration: The recommended dosage of Blincyto (blinatumomab) depends on the specific condition being treated and the patient’s body weight. It is typically administered as a continuous intravenous infusion at a specified dose and schedule determined by the healthcare provider. It’s important for patients to follow their healthcare provider’s instructions carefully and to receive treatment under medical supervision.

Adverse Reactions: The most commonly reported adverse reactions (≥ 20%) are pyrexia, hypokalemia, headache, peripheral edema, febrile neutropenia, nausea, rash, tremor, diarrhea and constipation. The most common serious adverse reactions (≥ 2%) are device-related infection, febrile neutropenia, sepsis, pyrexia, pneumonia, neutropenia, confusion, encephalopathy, infection, Staphylococcal bacteremia, tremor, and headache.

Contraindications: Blincyto should not be used in patients who have had a hypersensitive reaction to blinatumomab or any ingredients in the medication.

Storage Guidelines: Blincyto should be stored in its original carton in the refrigerator at a temperature between 36°F to 46°F (2°C to 8°C). Do not freeze or shake. Protect from light. Once removed from the refrigerator, Blincyto can be stored at room temperature up to 77°F (25°C) for up to 48 hours. Avoid returning to the refrigerator once it has been stored at room temperature.


Nitin Goswami

Nitin Goswami joined us as an Editor in 2020. He covers all the updates in the field of Pharmaceutical, Business Healthcare, Health News, Medical News, and Pharma News.

Leave a Reply

Close Menu